Wallace Audrey S, Nelson Jay P, Wang Zhenyu, Dale Paul S, Biedermann Gregory B
Department of Radiation Oncology, University of Alabama Birmingham Medical Center, Birmingham, AL, USA.
University of Missouri Columbia School of Medicine, Columbia, MO, USA.
Breast J. 2018 Jan;24(1):12-15. doi: 10.1111/tbj.12832. Epub 2017 Jul 4.
Accelerated partial breast irradiation (APBI) is an increasingly utilized modality for early stage breast cancer as part of breast conservation therapy (BCT). There remains concern regarding local recurrence, requiring more frequent post-radiation surveillance imaging. The purpose of this study is to determine clinical significance of frequent surveillance in this perceived higher risk population. Patients treated at a community academic medical center from 2005 to 2013 with partial breast radiation were retrospectively identified. All patients were treated with lumpectomy followed by balloon based APBI. Diagnostic, clinical, radiographic, and outcomes data were collected. One hundred and sixty-nine patients were identified. Median age at time of diagnosis was 63. Stage was 0, I, and II in 27%, 64%, and 9%, respectively. Most patients had pure invasive ductal cancer. Ninety-two percent and 99% of patients had imaging performed by 6 and 12 months (± 3 months) respectively. Median interval between end of radiation and first image, and subsequent 3 images were 6, 6, 9, and 12 months, respectively. Median follow-up was 49 months for all patients (range 7-106). Six patients experienced local recurrence: 4 invasive, all clinically detected, and none within the first 2 years. One patient had mammographically detected recurrent ductal carcinoma in situ. No mammographic images within the first year lead to diagnosis of recurrent cancer. APBI via balloon base brachytherapy offered women excellent locoregional control rates. Frequent mammographic surveillance did not result in increased detection of early recurrent disease. The result of our study are in line with the Choosing Wisely campaign recommendations to perform no more than annual follow-up for women who have completed radiation as part of BCT, with first imaging done at 6-12 months. We recommend mammographic surveillance be performed no more frequently than annually, with first image after BCT to be done 12 months from completion of radiation.
加速部分乳腺照射(APBI)作为保乳治疗(BCT)的一部分,在早期乳腺癌治疗中应用越来越广泛。对于局部复发仍存在担忧,这需要更频繁的放疗后监测成像。本研究的目的是确定在这个被认为风险较高的人群中频繁监测的临床意义。对2005年至2013年在社区学术医疗中心接受部分乳腺放疗的患者进行回顾性识别。所有患者均接受保乳手术,随后进行基于球囊的APBI。收集诊断、临床、影像学和结局数据。共识别出169例患者。诊断时的中位年龄为63岁。分期为0期、I期和II期的患者分别占27%、64%和9%。大多数患者患有纯浸润性导管癌。分别有92%和99%的患者在6个月和12个月(±3个月)时进行了成像检查。放疗结束至首次成像以及随后3次成像的中位间隔分别为6个月、6个月、9个月和12个月。所有患者的中位随访时间为49个月(范围7 - 106个月)。6例患者出现局部复发:4例为浸润性,均为临床检测到,且在最初2年内均未出现复发。1例患者在乳腺钼靶检查中发现复发性导管原位癌。第一年的乳腺钼靶图像均未导致复发性癌症的诊断。通过基于球囊的近距离放疗进行APBI为女性提供了出色的局部区域控制率。频繁的乳腺钼靶监测并未导致早期复发性疾病的检出率增加。我们的研究结果与“明智选择”运动的建议一致,即对于已完成作为BCT一部分放疗的女性,随访不超过每年一次,首次成像在6 - 12个月进行。我们建议乳腺钼靶监测的频率不超过每年一次,BCT后的首次成像应在放疗结束后12个月进行。